Genset of Paris said it has raised $7 million in a new round offinancing. The investors included Burr Egan Deleage & Co., a SanFrancisco-based venture capital firm; S.R. One Ltd., the fundcreated by SmithKline Beecham; and SoFinnova Inc., a Frenchventure capital firm.

Genset is developing synthetic nucleotides, both RNA and DNA,for use as research, diagnostic and therapeutic agents. Fortherapeutics, the company is developing antisense, anti-viralagents. Its antisense compounds are patented circularphosphodiester oligonucleotides resistant to cellular nucleasesand targeted to herpes simplex virus 1. Genset is alsodeveloping ribozymes targeted against hepatitis B virus.

Genset also makes catalog and custom oligonucleotides. InNovember 1990 the company signed a $2.5 million salescontract for custom nucleotides for the human genome projectin France. Genset can now make 300 nucleotides daily, andgram quantities of synthetic DNA for clients.

(c) 1997 American Health Consultants. All rights reserved.